Trial Information - Phase I

An Open-Label, Multicenter Phase I Dose Escalation Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics and Maximum Tolerated Dose of VIP152 (BAY 1251152) as monotherapy or in combination with KEYTRUDA® (pembrolizumab) in Subjects with Advanced Cancer

Protocol ID: VNC-152-101

Sponsor: Vincerx Pharma, Inc.

Status: OPEN TO ENROLLMENT

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724